ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+2.96%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$145M
AUM Growth
+$145M
(-25%)
Cap. Flow
-$41.7M
Cap. Flow
% of AUM
-28.69%
Top 10 Holdings %
Top 10 Hldgs %
61.57%
Holding
40
New
11
Increased
4
Reduced
15
Closed
10
Top Buys
| 1 |
Centene
CNC
|
$12M |
| 2 |
Alkermes
ALKS
|
$7.49M |
| 3 |
Kymera Therapeutics
KYMR
|
$5.98M |
| 4 |
Aclaris Therapeutics
ACRS
|
$5.55M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$5.45M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$11.6M |
| 2 |
UnitedHealth
UNH
|
$10.9M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$9.37M |
| 4 |
Kura Oncology
KURA
|
$7.84M |
| 5 |
Arcus Biosciences
RCUS
|
$6.64M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Centene
CNC
$14.3B
| $12M | 8.25% | +164,489 | New | +$12M |
|
2
AstraZeneca
AZN
$248B
| $10.5M | 7.25% | 176,010 -42,908 | -20% | -$2.57M |
|
3
Sotera Health
SHC
$4.65B
| $10.2M | 7.02% | 421,341 -45,936 | -10% | -$1.11M |
|
|
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $9.7M | 6.67% | 142,246 -20,889 | -13% | -$1.42M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.37M | 6.44% | 57,979 +33,716 | +139% | +$5.45M |
|
6
Jazz Pharmaceuticals
JAZZ
$7.75B
| $9.36M | 6.44% | 52,702 -21,462 | -29% | -$3.81M |
|
7
Insulet
PODD
$23.9B
| $7.95M | 5.46% | 28,943 -14,240 | -33% | -$3.91M |
|
|
8
Alkermes
ALKS
$4.78B
| $7.49M | 5.15% | +305,245 | New | +$7.49M |
|
9
Adaptive Biotechnologies
ADPT
$2.01B
| $6.87M | 4.72% | 168,172 -119,318 | -42% | -$4.88M |
|
10
ESSA Pharma
EPIX
$11.4M
| $6.07M | 4.17% | 212,525 -71,934 | -25% | -$2.06M |
|
|
11
Kymera Therapeutics
KYMR
$2.95B
| $5.98M | 4.11% | +123,363 | New | +$5.98M |
|
|
12
Aclaris Therapeutics
ACRS
$209M
| $5.55M | 3.81% | +315,834 | New | +$5.55M |
|
|
MREO
13
Mereo BioPharma
MREO
$272M
| $5.13M | 3.53% | 1,618,328 +555,064 | +52% | +$1.76M |
|
14
Biodesix
BDSX
$62.6M
| $5.04M | 3.46% | 381,378 -62,673 | -14% | -$828K |
|
|
ASLN
15
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $3.94M | 2.71% | 1,194,070 -158,507 | -12% | -$523K |
|
16
PMV Pharmaceuticals
PMVP
$74.2M
| $3.48M | 2.39% | 101,776 -16,352 | -14% | -$559K |
|
17
Hologic
HOLX
$14.9B
| $3.08M | 2.12% | +46,184 | New | +$3.08M |
|
18
Guardant Health
GH
$8.41B
| $3.04M | 2.09% | 24,443 -37,466 | -61% | -$4.65M |
|
19
Amicus Therapeutics
FOLD
$2.34B
| $2.89M | 1.98% | +299,284 | New | +$2.89M |
|
|
AVDL
20
Avadel Pharmaceuticals
AVDL
$1.43B
| $2.69M | 1.85% | 399,776 -312,595 | -44% | -$2.1M |
|
21
argenx
ARGX
$43.6B
| $2.44M | 1.68% | +8,104 | New | +$2.44M |
|
22
Forte Biosciences
FBRX
$137M
| $2.23M | 1.53% | 66,390 +13,193 | +25% | +$444K |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $1.92M | 1.32% | +2,979 | New | +$1.92M |
|
24
iTeos Therapeutics
ITOS
| $1.57M | 1.08% | 61,248 -41,038 | -40% | -$1.05M |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $1.57M | 1.08% | +51,039 | New | +$1.57M |
|